-
公开(公告)号：US20180142349A1
公开(公告)日：2018-05-24
申请号：US15576215
申请日：2016-05-20
Applicant: Universität ULM
Inventor： Anton Reiser , Manfred Madel , Florian Huber , Klaus Thonke
IPC: C23C16/40
CPC classification number: C23C16/407 , C30B25/00 , C30B29/16
Abstract: A method for depositing zinc oxide on a substrate is disclosed. In an embodiment, the method includes reducing, in a first stage, a source material comprising zinc oxide to zinc which is gaseous at reaction conditions by contacting the source material with a gaseous reducing agent, transporting, in a second stage locally separate from the first stage, the gaseous zinc to the substrate, wherein the gaseous zinc is converted to zinc oxide by adding an oxidizing agent; and depositing the zinc oxide on a surface of the substrate, wherein the gaseous reducing agent is methane or a thermal decomposition product of at least one precursor, which is thermally decomposed at the reaction conditions of the first stage so that methane, methyl radicals and/or acetone is released.
-
22.发明授权公开(公告)号：US09034599B2
公开(公告)日：2015-05-19
申请号：US14164903
申请日：2014-01-27
Applicant: Universität Ulm
Inventor： Jörg Wiedenmann , Simone Kredel , Franz Oswald , Gerd Ulrich Nienhaus
CPC classification number: C07K14/43504 , C07K14/43595 , G01N33/582
Abstract: DNA encoding a monomeric variant of red fluorescent protein eqFP611 comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5. DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.
Abstract translation: 编码红色荧光蛋白eqFP611的单体变体的DNA，其包含选自SEQ ID No.1，SEQ ID No.3和SEQ ID No.5的氨基酸序列。包含选自下组的核苷酸序列的DNA： SEQ ID No.2，SEQ ID No.4和SEQ ID No.6。
-
公开(公告)号：US20210355178A1
公开(公告)日：2021-11-18
申请号：US17255228
申请日：2019-06-21
Applicant: Universität Ulm
Inventor： Christoph Schmidt , Markus Huber-Lang
IPC: C07K14/47
Abstract: The present invention relates to a multi-module polypeptide comprising (i) an Fc receptor binding module; (ii) a first complement control protein repeat (CCP) module; and (iii) a second CCP module binding to at least one host cell surface marker, to complement factor C3b, to complement factor C4b, to a degradation product of complement factor C3b, and/or to a degradation product of complement factor C4b; wherein said second CCP module is C-terminal of said Fc receptor binding module and of said first CCP module. The present invention also relates to a polynucleotide encoding said multi-module polypeptide, and to said multi-module polypeptide for use in medicine, in particular for use in treating and/or preventing inappropriate complement activation and/or a disease having inappropriate complement activation as a symptom. Moreover, the present invention relates to an in vitro method for preventing or reducing the degree of complement activation comprising applying a multi-module polypeptide to a reaction mixture, a tissue, and/or an organ comprising complement factors, thereby preventing or reducing the degree of complement activation in said reaction mixture, tissue, and/or organ.
-
公开(公告)号：US20210122771A1
公开(公告)日：2021-04-29
申请号：US17255963
申请日：2019-06-28
Applicant: The Regents of the University of California , UNIVERSITÄT DUISBURG-ESSEN , UNIVERSITÄT ULM
Inventor： Gal Bitan , Thomas Schrader , Jan Münch , Christian Heid , Andrea Sowislok , Annika Röcker , Danielle Bouquio , Ravinder Malik
Abstract: In various embodiments new molecular tweezers compounds are provided. The compounds described herein (e.g., molecular tweezers) are believed to be useful for inhibiting protein aggregation (or disaggregating aggregated proteins). In certain embodiments the compounds described herein (e.g., molecular tweezers) are believed to be useful in the treatment of pathologies characterized by protein aggregation (e.g., amyloidopathies), and/or in the treatment of brain or spinal cord damage associated with acute trauma, stroke, and the like, and/or in the treatment of lysosomal storage diseases, and/or in the treatment of lipofuscin-related disorders, and in various viral infections.
-
25.发明申请公开(公告)号：US20170348727A1
公开(公告)日：2017-12-07
申请号：US15537545
申请日：2015-12-14
Applicant: UNIVERSITÄT ULM
Inventor： Steffen STREHLE , Daniel Markus ROSSKOPF , Andreas Magnus PROBST
CPC classification number: B05D1/28 , B81C1/00373 , B81C2201/0185 , B81C2201/0187 , B82B3/0066 , H05K1/0306 , H05K1/09 , H05K3/102 , H05K3/1275 , H05K2201/026 , H05K2201/09036 , H05K2201/09045 , H05K2203/0108 , H05K2203/0271 , H05K2203/0528
Abstract: The invention relates to a method for producing a substrate structured by nanowires, characterized in that no lubricant and no lithographic resist mask is used in the method, and only by moving a donor substrate having nanowires relative to a substrate and by locally tribological properties on the surface of the substrate, a specified number of nanowires is deposited selectively at locally defined points of the substrate. The invention further relates to a substrate that can be produced using the method according to the invention, and which selectively contains a specified number of nanowires on a surface at locally defined points. The invention further relates to the use of the substrate according to the invention in microelectronics, microsystems technology, and/or micro-sensor systems.
-
Patent Agency Ranking
公开(公告)号：WO2023016826A2
公开(公告)日：2023-02-16
申请号：PCT/EP2022/071294
申请日：2022-07-28
Applicant: VACCINVENT GMBH , UNIVERSITÄT ULM
Inventor： JUMAA-WEINACHT, Hassan
Abstract: The invention relates to a pharmaceutical composition comprising an IgM antibody or a fragment thereof and a therapeutic antibody, wherein the IgM antibody specifically binds to the therapeutic antibody. The invention further relates to a method of treatment of a disease or disorder, the method comprising the steps of: a) administering an effective dose of a therapeutic antibody; and b) administering a corresponding dose of an IgM antibody or a fragment thereof, wherein the IgM antibody specifically binds to the therapeutic antibody.
-
公开(公告)号：WO2022162203A1
公开(公告)日：2022-08-04
申请号：PCT/EP2022/052148
申请日：2022-01-28
Applicant: VACCINVENT GMBH , UNIVERSITÄT ULM
Inventor： JUMAA-WEINACHT, Hassan , AMENDT, Timm , YOUNG, Marc
Abstract: The invention pertains to methods and means for the targeted modulation of B-cell mediated immune responses by bringing into contact a B-cell with a specific ratio of soluble single monovalent antigens and complexed multivalent antigens. The targeted modulation of B-cell immunity can be used in mammals for the diagnosis and therapy of various conditions associated with antibody-mediated immunity. Such conditions include proliferative disorders such as cancer, autoimmune disorders, pathogenic infections, inflammatory diseases, allergies and food intolerances. The invention is predicated on the observation that complexed multivalent antigenic structures induce a strong IgG type antibody B-cell response while surprisingly monovalent antigenic structures harbour the ability to supress such IgG responses, or even induce in the case of autoantigens protective IgM responses. The invention in this regard offers methods, compositions, therapeutics, diagnostics and food additives.
-
公开(公告)号：WO2021078735A1
公开(公告)日：2021-04-29
申请号：PCT/EP2020/079494
申请日：2020-10-20
Applicant: UNIVERSITÄT ULM
Inventor： KOCHANEK, Stefan , KRUTZKE, Lea , STEINER, Robin , LÜBBERS, Olivia
IPC: C12N15/86 , A61K35/761 , C12N15/34 , C12N5/10
Abstract: The invention discloses a human adenovirus species C having a capsid which comprises a modified adenovirus hexon protein, wherein the modified adenovirus hexon protein has a modified HVR1 region, wherein the modified HVR1 region has the sequence DEAATALEINLKKKKQAEQQ (SEQ ID NO.: 1). The invention further discloses the adenovirus of the disclosure for use in treating or preventing a human disease. The invention further discloses a nucleic acid encoding the modified adenovirus hexon protein. The invention further discloses the use of an adenovirus according to the disclosure for transducing mesenchymal stromal cells (MSCs) or tumor cells. The invention further discloses an in vitro method for transducing MSCs and a transduced MSC obtainable by the method. The invention further discloses the transduced MSC of the disclosure for use in treating a disease.
-
公开(公告)号：WO2019096751A2
公开(公告)日：2019-05-23
申请号：PCT/EP2018/080981
申请日：2018-11-12
Applicant: UNIVERSITÄT ULM INSTITUT FÜR OPTOELEKTRONIK
Inventor： EBELING, Karl Joachim , MICHALZIK, Rainer
Abstract: Die vorliegende Erfindung betrifft allgemein ein Verfahren zur Messung wenigstens eines Merkmals in einem zu untersuchenden Medium, vorzugsweise zur Bestimmung des Brechungsindex des Mediums. Die Erfindung betrifft ferner eine für die Bestimmung des Brechungsindex eines Mediums geeignete Vorrichtung, umfassend ein für die Durchführung des Verfahrens geeignetes optisches Element. Das optisches Element umfasst eine Grenzfläche, welche ausgebildet ist, flächig einen direkten Kontakt mit dem zu untersuchenden Medium während der Messung zu bilden, wobei diese Grenzfläche des optischen Elements mit einem als Resonator wirkenden Schichtsystem ausgestattet ist, der Mehrfachreflexionen für auftreffende elektromagnetische Strahlung ermöglicht.
-
30.发明申请
公开(公告)号：WO2018091589A1
公开(公告)日：2018-05-24
申请号：PCT/EP2017/079457
申请日：2017-11-16
Applicant: UNIVERSITÄT ULM
Inventor： HORVAT, Sebastian , DACCACHE, Layal , JACOB, Timo , FARKAS, Attila
IPC: G01N21/65
CPC classification number: G01N21/65 , G01N2021/651
Abstract: Erfindungsgemäß wird eine Messzelle für die Raman-Spektroskopie an einer Fest-Flüssig-Grenzfläche bereitgestellt. Die Messzelle besteht im Wesentlichen aus einem Grundkörper und zumindest Teilen einer Arbeitselektrode, Referenzelektrode und Gegenelektrode. In der erfindungsgemäßen Messzelle bildet ein Teil der Arbeitselektrode den Boden der Messzelle, der mit Elektrolyt in Kontakt steht, wobei die elektrische Kontaktierung dieses Teils der Arbeitselektrode an einem Ort der Messzelle erfolgt, der nicht mit Elektrolyt in Kontakt steht. Dies bewirkt, dass bereits bei sehr geringen Elektrolytmengen unerwünschte Potentialverschiebungen vermieden werden und Qualität, Auflösung und Standardabweichungen der mit der Messzelle aufgenommenen Spektren besser sind als im Stand der Technik. Die Anordnung des zweiten Teils der Arbeitselektrode in einer Ausnehmung an der Unterseite des Grundkörpers bewirkt eine einfache und schnelle Reinigung der Messzelle. Es werden zudem Verwendungen der erfindungsgemäßen Messzelle vorgeschlagen.
-
-
-
-
-
-
-
-
-
Search Results
234
records
(took 0.021 seconds)
